These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 29870498)

  • 21. Cardiovascular disease in lupus: insights and updates.
    Knight JS; Kaplan MJ
    Curr Opin Rheumatol; 2013 Sep; 25(5):597-605. PubMed ID: 23846339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus.
    Couture J; Silverman ED
    Curr Opin Rheumatol; 2016 Sep; 28(5):488-96. PubMed ID: 27341622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis.
    Lu X; Wang Y; Zhang J; Pu D; Hu N; Luo J; An Q; He L
    Int Immunopharmacol; 2021 May; 94():107466. PubMed ID: 33636561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of premature atherosclerosis in systemic lupus erythematosus patients with and without nephritis.
    Sharma SK; Rathi M; Sahoo S; Prakash M; Dhir V; Singh S
    Lupus; 2016 Apr; 25(5):525-31. PubMed ID: 26678442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of neutrophils in the pathogenesis of systemic lupus erythematosus.
    Smith CK; Kaplan MJ
    Curr Opin Rheumatol; 2015 Sep; 27(5):448-53. PubMed ID: 26125102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.
    Somers EC; Zhao W; Lewis EE; Wang L; Wing JJ; Sundaram B; Kazerooni EA; McCune WJ; Kaplan MJ
    PLoS One; 2012; 7(5):e37000. PubMed ID: 22606325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.
    Cederholm A; Svenungsson E; Stengel D; Fei GZ; Pockley AG; Ninio E; Frostegård J
    Arthritis Rheum; 2004 Sep; 50(9):2869-76. PubMed ID: 15457454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review.
    Kirchler C; Husar-Memmer E; Rappersberger K; Thaler K; Fritsch-Stork R
    Autoimmun Rev; 2021 May; 20(5):102794. PubMed ID: 33722754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus.
    Ding X; Xiang W; He X
    Front Immunol; 2020; 11():581385. PubMed ID: 33262760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic lupus erythematosus, atherosclerosis, and autoantibodies.
    Zampieri S; Iaccarino L; Ghirardello A; Tarricone E; Arienti S; Sarzi-Puttini P; Gambari P; Doria A
    Ann N Y Acad Sci; 2005 Jun; 1051():351-61. PubMed ID: 16126977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus.
    Richter P; Cardoneanu A; Rezus C; Burlui AM; Rezus E
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular disease risk in systemic lupus erythematous: Certainties and controversies.
    Atzeni F; Rodríguez-Pintó I; Cervera R
    Autoimmun Rev; 2024 Oct; 23(10):103646. PubMed ID: 39321952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study.
    Hermansen ML; Lindhardsen J; Torp-Pedersen C; Faurschou M; Jacobsen S
    Rheumatology (Oxford); 2017 May; 56(5):709-715. PubMed ID: 28053276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic lupus erythematosus and cardiovascular disease.
    Frostegård J
    J Intern Med; 2023 Jan; 293(1):48-62. PubMed ID: 35982610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLE, atherosclerosis and cardiovascular disease.
    Frostegård J
    J Intern Med; 2005 Jun; 257(6):485-95. PubMed ID: 15910552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus.
    Clancy R; Ginzler EM
    Rheum Dis Clin North Am; 2010 Feb; 36(1):145-60, ix-x. PubMed ID: 20202596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients.
    Yang L; Tao J; Tang X; Wang Y; He X; Xu G; Ren Y; Tu Y
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):95-101. PubMed ID: 21851424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance.
    Liu T; Shi N; Zhang S; Silverman GJ; Duan XW; Zhang S; Niu H
    Lupus; 2020 Mar; 29(3):273-282. PubMed ID: 32075511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age.
    Medeiros MM; Xavier de Oliveira ÍM; Ribeiro ÁT
    Rheumatol Int; 2016 Jan; 36(1):117-24. PubMed ID: 26149124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.